GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acusphere Inc (OTCPK:ACUS) » Definitions » Intrinsic Value: Projected FCF

Acusphere (Acusphere) Intrinsic Value: Projected FCF : $0.00 (As of May. 28, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Acusphere Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-28), Acusphere's Intrinsic Value: Projected FCF is $0.00. The stock price of Acusphere is $1.0E-5. Therefore, Acusphere's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Acusphere's Intrinsic Value: Projected FCF or its related term are showing as below:

ACUS's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.59
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Acusphere Intrinsic Value: Projected FCF Historical Data

The historical data trend for Acusphere's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acusphere Intrinsic Value: Projected FCF Chart

Acusphere Annual Data
Trend Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Acusphere Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acusphere's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Acusphere's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acusphere's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acusphere's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Acusphere's Price-to-Projected-FCF falls into.



Acusphere Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Acusphere  (OTCPK:ACUS) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Acusphere's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=1.0E-5/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acusphere Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Acusphere's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Acusphere (Acusphere) Business Description

Traded in Other Exchanges
N/A
Address
99 Hayden Avenue, Suite 385, Lexington, MA, USA, 02421
Acusphere Inc is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology.
Executives
Martyn D Greenacre director 41 MOORES ROAD, FRAZER PA 19355
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Sandra L Fenwick director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Frederick W Ahlholm officer: VP Finance C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
John F Thero other: Former Senior VP/CFO C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Kate Mitchell director 950 TOWER LANE, STE 700, FOSTER CITY CA 94404
Bank Of America Corp /de/ 10 percent owner BANK OF AMERICA CORPORATE CENTER, 100 N TRYON ST, CHARLOTTE NC 28255
Bank Of America Na 10 percent owner 100 N. TRYON STREET, CHARLOTTE NC 28255
Nb Holdings Corp 10 percent owner 100 NORTH TRYON STREET, CHARLOTTE NC 28255
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154

Acusphere (Acusphere) Headlines

No Headlines